On September 4, 2024 Caris Life Sciences (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, reported that the company and collaborators from the biopharma industry and leading cancer centers, including those within the Caris Precision Oncology Alliance (POA), will collectively present seven studies across a wide range of tumor types at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2024 in Barcelona, Spain from September 13-17, 2024 (Booth #608) (Press release, Caris Life Sciences, SEP 4, 2024, View Source [SID1234646354]). The findings demonstrate the power of Caris’ comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient’s diagnosis, prognosis, care plan and response to treatment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The research being presented at this year’s ESMO (Free ESMO Whitepaper) Congress is a testament to Caris’ continued commitment to data-driven molecular innovation and the power of our ever-expanding network of collaborators to answer some of today’s pressing questions in precision oncology," said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. "The findings underscore the critical role of comprehensive profiling in cancer care and the power of large clinico-genomic datasets to enable the identification of new biomarkers with clinical implications across diverse tumor types. Through extensive sequencing and data analysis efforts, we are unlocking new avenues for tailored therapies to revolutionize cancer treatment."
"Our comprehensive molecular profiling coupled with rich clinical data is enabling Caris to help clinicians make the best treatment choices, researchers to discover novel cancer biology, and the biopharmaceutical industry to develop the next breakthrough medicines," said Caris President David Spetzler, MS, PhD, MBA. "Our vast real-world evidence from over 689,000 cases, including over 550,000 with matched molecular data and outcomes, enables our team and research collaborators to better understand the biological hallmarks of cancers and how they impact clinical outcomes, paving the way for personalized therapies and improved patient outcomes."
Mini oral presentations include:
Metastatic hormone receptor-positive breast cancer outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real world data analysis of genomics and targeted therapy sequencing. (Abstract Number: 342MO)
September 15, 2024
Atlas of tertiary lymphoid structures in solid tumors: Genomic features and prediction of response to immunotherapy. (Abstract Number: 75MO)
September 16, 2024
Poster presentations include:
Impact of TLS Status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors. (Abstract Number: 1051P)
September 14, 2024
Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial endometrioid adenocarcinoma (EEA). (Abstract Number: 739P)
September 14, 2024
METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence. (Abstract Number: 1303P)
September 14, 2024
Genomic landscape & prognostic impact of HER2 low-expressing tumors. (Abstract Number: 126P)
September 15, 2024
Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC). (Abstract Number: 1653P)
September 15, 2024
Poster and abstract summaries highlighting the Caris research presented at ESMO (Free ESMO Whitepaper) 2024 will be available onsite at Caris’ Booth #608. The full abstracts will be available on the Caris website at the event’s conclusion.
The Caris POA includes 95 cancer centers, academic institutions, research consortia and healthcare systems, including 46 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. Caris and POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.